Principal Investigator
Frances Valdes
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240808
Clinical Trial Summary
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, as monotherapy and in combination in participants with advanced solid tumors
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Contact Information
Phone Number
305-243-2647